ArticleGenes & diseases2026
DLL3 serves as a pivotal hub bridging malignant progression and immunosuppression in NECC with therapeutic implications validated via the organoid-TIL co-culture system.
Article in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine carcinoma of the cervix (NECC) represents a highly aggressive cervical cancer subtype with a poorly characterized tumor immune microenvironment (TIME) and unclear oncogenic mechanisms. Herein, through scRNA-seq analysis, we identified neuronal progenitor cells (NPCs) exhibiting high expression of NECC markers (SYN/INSM1) as putative malignant cells, and delineated three distinct NPC states along their developmental trajectory. Notably, we observed extensive infiltration of both naïve and exhausted T cells, collaboratively shaping an immunosuppressive TIME. Cellular communication analysis discovered DLL3's interaction with NOTCH2 on NPCs and NOTCH1/2 on tumor-infiltrating lymphocytes, with spatial relationships validated by multicolor immunohistochemistry staining. Functional experiments demonstrated that DLL3 promoted tumor cell proliferation and invasion, whereas co-culture assays revealed that DLL3 contributed to T cell exhaustion and impaired T cell activation, collectively proving DLL3 as a central molecular hub coordinating both malignant progression and immunosuppression. Moreover, we verified heightened and specific DLL3 expression in NECC tissues through immunohistochemistry staining, underscoring DLL3 as a promising therapeutic target for NECC. Significantly, we not only innovatively established NECC-derived organoids replicating cellular morphology, neuroendocrine differentiation features, and genetic characteristics of parental tumors, but also co-cultured organoids with tumor-infiltrating lymphocytes to assess the therapeutic efficacy of AMG757 targeting DLL3. Remarkably, the combination of AMG757 targeting DLL3 with chemotherapy (etoposide + cisplatin) induced substantial T cell aggregation and activation and heightened immunogenic cell death, offering novel insights into NECC treatment. Overall, the study provides comprehensive insights into NECC TIME and tailored therapeutic approaches beyond traditional therapy for NECC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.